Abstract CT552: RATIONALE 304: Tislelizumab (TIS) plus chemotherapy versus chemotherapy alone as first-line (1L) treatment for non-squamous (non-sq) NSCLC in patients (pts) aged 65-75 yearsdoi:10.1158/1538-7445.
Overall, 332 patients (n=222 [A]; n=110 [B]) received treatment. With a median study follow-up of 9.8 months, PFS was significantly longer with tislelizumab plus chemotherapy compared with chemotherapy alone (media...
7.WangJ, Yu X, Lu S, et al. Phase 3 study of tislelizumab pluschemotherapyversus chemotherapy alone as first-line treatment foradvancedsquamous non-small cell lung cancer. Poster presented at:AmericanSociety of Clinical Oncology May 29-31, 2020; Chicago, IL 8.ShunLu, et al. 2020 ESMO ...
10 In a phase 3 study, addition of tislelizumab to chemotherapy resulted in significantly improved progression-free survival (PFS) compared with chemotherapy alone in patients with stage IIIB or IV squamous NSCLC (RATIONALE 307; BGB-A317-307 [NCT03594747]).11 Here, we present the efficacy ...
10 In a phase 3 study, addition of tislelizumab to chemotherapy resulted in significantly improved progression-free survival (PFS) compared with chemotherapy alone in patients with stage IIIB or IV squamous NSCLC (RATIONALE 307; BGB-A317-307 [NCT03594747]).11 Here, we present the efficacy ...